NL-OMON30891已完成3 期
A phase 3, randomized, double-blind, active controlled (enoxaparin 40 mg QD), parallel-group, multi-center study to evaluate the safety and efficacy of Apixban in subjects ondergoing elective total knee replacement surgery. - ADVANCE-2-CV185047
Bristol-Myers Squibb0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Subjects must undergo elective surgery for total knee replacement
- •2) At least 18 years of age
- •3) Subjects must be willing and able to undergo bilateral contrast venography
排除标准
- •1) Known or suspected bleeding or coagulation disorder in the subject or a first degree relative
- •2) Known or suspected history of heparin-induced thrombocytopenia
- •3) Active bleeding or at high risk for bleeding
- •4) Need for ongoing treatment with a parenteral or oral anticoagulant
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI).Clostridium difficile infection (CDI)MedDRA version: 20.0Level: PTClassification code 10054236Term: Clostridium difficile infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001642-10-FRSummit (Oxford) Limited680
进行中（未招募）
1 期
Comparison of ridinilazole versus vancomycin treatment for Clostridium difficile infectioClostridium difficile infection (CDI)MedDRA version: 20.0Level: PTClassification code 10054236Term: Clostridium difficile infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001642-10-LVSummit (Oxford) Limited680
进行中（未招募）
1 期
Comparison of ridinilazole versus vancomycin treatment for Clostridium difficile infectioClostridium difficile infection (CDI)MedDRA version: 20.0 Level: PT Classification code 10054236 Term: Clostridium difficile infection System Organ Class: 10021881 - Infections and infestationsEUCTR2017-001642-10-ESSummit (Oxford) Limited680
进行中（未招募）
1 期
Comparison of ridinilazole versus vancomycin treatment for Clostridium difficile infectioEUCTR2017-001642-10-DESummit (Oxford) Limited680
进行中（未招募）
1 期
Comparison of ridinilazole versus vancomycin treatment for Clostridium difficile infectioClostridium difficile infection (CDI)MedDRA version: 20.0Level: PTClassification code 10054236Term: Clostridium difficile infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001641-27-BGSummit (Oxford) Limited680